How Peptides May Help Chest Pain: Preclinical Research Review
This comprehensive, evidence-based guide examines the latest published research on peptides for chest pain, providing researchers with an in-depth analysis of molecular mechanisms, preclinical findings, clinical trial data, and practical implications for laboratory investigation. With the peptide research landscape evolving rapidly, staying current on peptides for chest pain has become essential for investigators designing rigorous experimental protocols.
Over the past decade, research into peptides for chest pain has produced a substantial body of peer-reviewed evidence, spanning hundreds of published studies across leading scientific journals. This guide synthesizes the most impactful findings, highlights critical knowledge gaps, and identifies emerging research directions that are reshaping the field.
Whether you are an experienced peptide researcher or exploring this domain for the first time, this guide provides the scientific context needed to evaluate published evidence and design informed experiments. For high-purity research compounds, explore our complete selection of research peptides with third-party testing and Certificates of Analysis.
Table of Contents
- Tissue-Specific and Organ-Level Effects
- Structure-Activity Relationships
- Dose-Response Data and Optimal Concentrations
- Safety and Tolerability in Published Research
- Pharmacokinetic Profile and Bioavailability
- Clinical Trial Evidence and Human Data
- Comparative Analysis with Alternatives
- Genomic and Transcriptomic Evidence
- Research Protocol Recommendations
- Biomarker Analysis and Outcome Measures
- FAQ
- Shop Peptides
Tissue-Specific and Organ-Level Effects
Understanding tissue-specific and organ-level effects is fundamental to comprehensive peptides for chest pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining peptides for chest pain have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
For laboratory work, BPC-157 and TB-500 (Thymosin Beta-4) are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued peptides for chest pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Riera et al., 2017, establishing critical parameters for understanding these mechanisms.
Structure-Activity Relationships
Understanding structure-activity relationships is fundamental to comprehensive peptides for chest pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining peptides for chest pain have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Galluzzi et al., 2017, establishing critical parameters for understanding these mechanisms.
Dose-Response Data and Optimal Concentrations
Research into dose-response data and optimal concentrations has generated substantial evidence illuminating how peptides for chest pain interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for chest pain. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
Published studies frequently employ high-purity research compounds. BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs meet stringent purity requirements, verified by independent testing.
These findings demonstrate the multifaceted nature of peptides for chest pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Gwyer et al., 2019, establishing critical parameters for understanding these mechanisms.
Safety and Tolerability in Published Research
Investigation of safety and tolerability in published research represents an active frontier in peptides for chest pain research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for chest pain. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
Related research compounds include Tirzepatide and GHK-Cu (Copper Peptide), available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued peptides for chest pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Chen et al., 2016, establishing critical parameters for understanding these mechanisms.
Pharmacokinetic Profile and Bioavailability
Understanding pharmacokinetic profile and bioavailability is fundamental to comprehensive peptides for chest pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking peptides for chest pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
These findings demonstrate the multifaceted nature of peptides for chest pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Jastreboff et al., 2022, establishing critical parameters for understanding these mechanisms.
Clinical Trial Evidence and Human Data
Investigation of clinical trial evidence and human data represents an active frontier in peptides for chest pain research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Studies examining peptides for chest pain have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Published studies frequently employ high-purity research compounds. BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs meet stringent purity requirements, verified by independent testing.
These findings demonstrate the multifaceted nature of peptides for chest pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Wadden et al., 2023, establishing critical parameters for understanding these mechanisms.
Comparative Analysis with Alternatives
Understanding comparative analysis with alternatives is fundamental to comprehensive peptides for chest pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining peptides for chest pain have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
For laboratory work, BPC-157 and TB-500 (Thymosin Beta-4) are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued peptides for chest pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Goldstein et al., 2010, establishing critical parameters for understanding these mechanisms.
Genomic and Transcriptomic Evidence
Investigation of genomic and transcriptomic evidence represents an active frontier in peptides for chest pain research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Longitudinal research tracking peptides for chest pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
Related research compounds include KPV and Tesamorelin, available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued peptides for chest pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Zhang et al., 2020, establishing critical parameters for understanding these mechanisms.
Research Protocol Recommendations
The scientific literature on research protocol recommendations provides critical insights into peptides for chest pain research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to peptides for chest pain. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
Related research compounds include AOD 9604 and CJC-1295 No DAC, available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued peptides for chest pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Newman et al., 2019, establishing critical parameters for understanding these mechanisms.
Biomarker Analysis and Outcome Measures
Understanding biomarker analysis and outcome measures is fundamental to comprehensive peptides for chest pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining peptides for chest pain have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
For laboratory work, BPC-157 and TB-500 (Thymosin Beta-4) are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Wilding et al., 2021, establishing critical parameters for understanding these mechanisms.
Broader Implications
Understanding broader implications is fundamental to comprehensive peptides for chest pain investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking peptides for chest pain effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
Researchers investigating these mechanisms can access high-purity compounds including BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued peptides for chest pain investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Xu et al., 2018, establishing critical parameters for understanding these mechanisms.
Supplementary Evidence
Investigation of supplementary evidence represents an active frontier in peptides for chest pain research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Quantitative analysis of peptides for chest pain in preclinical models has revealed a complex pharmacological profile characterized by multiple interacting mechanisms. Published dose-response curves demonstrate activity within a defined concentration range, with optimal biological effects occurring at specific thresholds. Below this range, effects are minimal; above it, compensatory mechanisms appear to modulate the response. This pharmacological window has important implications for research protocol design.
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Published studies frequently employ high-purity research compounds. BPC-157 and TB-500 (Thymosin Beta-4) from Proxiva Labs meet stringent purity requirements, verified by independent testing.
These findings demonstrate the multifaceted nature of peptides for chest pain research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Newman et al., 2019, establishing critical parameters for understanding these mechanisms.
Frequently Asked Questions
How long until results are visible?
Timelines vary by model and endpoint. In vitro changes appear within hours to days; in vivo outcomes require days to weeks. Chronic studies may extend months. Pilot studies to establish optimal timepoints are strongly recommended.
Is this research clinically relevant?
While most peptides for chest pain research is preclinical, translational potential is considerable. Related compounds have progressed through clinical trials. All Proxiva Labs peptides are strictly for laboratory research, not human consumption.
What is peptides for chest pain?
Peptides for chest pain encompasses a specific area of peptide science attracting significant research interest due to potential applications in biological research. Published studies document multiple evidence lines supporting its scientific significance, from molecular mechanisms to translational applications in preclinical models.
Where can I find high-quality research peptides?
Proxiva Labs offers research-grade peptides with ?98% HPLC purity and Certificates of Analysis. Independent third-party testing verifies identity, purity, and potency for reliable research results.
What does the research say about peptides for chest pain?
Peer-reviewed literature on peptides for chest pain spans multiple journals, providing growing evidence supporting continued investigation. Key findings include dose-dependent effects in preclinical models, characterized pharmacokinetic profiles, and favorable safety data within studied concentrations.
What equipment is needed?
Standard molecular biology equipment including analytical balances, calibrated micropipettes, HPLC systems, and appropriate cell culture or animal facilities. Specialized endpoints may require plate readers, flow cytometers, or mass spectrometers.
Related Research Resources
Explore more from Proxiva Labs:
- Tirzepatide — a dual GIP/GLP-1 receptor agonist with emerging metabolic research applications
- KPV — an alpha-MSH fragment studied for anti-inflammatory and antimicrobial effects
- L-Carnitine — an amino acid derivative studied for fatty acid transport and energy metabolism
- Semax — a synthetic ACTH analog studied for neuroprotective and cognitive effects
- GHK-Cu (Copper Peptide) — a copper-binding tripeptide studied for skin remodeling and gene expression modulation
- Browse All Research Guides
- Shop All Peptides
- Third-Party Test Results
Shop Research Peptides at Proxiva Labs
USA-Made • ?98% HPLC Purity • Third-Party Tested • Free Shipping $150+ • COA Included
a gastric pentadecapeptide studied for tissue repair and wound healing
a 43-amino acid peptide studied for tissue regeneration and anti-inflammatory ef
a mitochondrial-derived peptide studied for metabolic regulation and exercise mi
a dual GIP/GLP-1 receptor agonist with emerging metabolic research applications
a synthetic melanocortin peptide studied for melanogenesis and photoprotection
a growth hormone releasing hormone analog studied for sustained GH elevation
an amino acid derivative studied for fatty acid transport and energy metabolism
a GLP-1 receptor agonist studied for metabolic and weight management research